Scientists figure out that a key gene which may prevent early labor, is switched off by the inflammation of the uterus during labor, opening up new treatments for the prevention of premature births.

The process behind how women go into normal term labour is still poorly understood, but it is vital that it happens at the right time when the baby is ready to be born and can survive. Currently there are few reliable drugs that can be used to stop labour if it starts too early.
The ground breaking research, led by Dr Neil Chapman from the University of Sheffield's Medical School in collaboration with a team of multidisciplinary researchers from Sheffield Teaching Hospitals NHS Foundation Trust and the Universities of Newcastle and Nottingham, focuses on how inflammation in the uterus affected an experimental class of drugs called histone deacetylase inhibitors (HDACi), which aim to delay labour when it starts prematurely.
In laboratory studies using tissue samples taken from pregnant women, these experimental drugs have been shown to stop the womb contracting. However when the research team analysed a chemical released during uterine inflammation called TNF, they found that this actually caused muscle contraction to start again even when the HDACi drug had successfully stopped womb-muscle contraction.
"Premature birth remains the biggest cause of neonatal mortality, primarily because we still do not know enough about the biochemistry and physiology of how the uterus goes into labour in normal term pregnancies. Our work demonstrates that while this experimental drug can stop the womb contracting, it cannot stop the inflammation associated with normal labour from switching off the genes which ensure the uterus does not start to contract too early. This means this class of drug may not be a suitable medication to give a pregnant woman when her labour starts prematurely because it cannot over-ride the inflammation already present, "said Dr. Chapman. He added: "Our research is a major step forward in unlocking the mysteries behind the processes of normal labour. We have shown that the inflammation of the uterus switches off the genes which stops labour occurring too early.Understanding how to prevent this inflammation or how to stop it blocking those key genes needed to stop contraction of the womb would lead to new treatments to prevent premature births."
Dr Raheela Khan, a key member of the research team from the University of Nottingham highlighted the significance of the findings. She said: "Although the details of the process through which TNF reverses uterine relaxation remain to be worked out, this exciting finding illustrates a potentially novel target of action for this molecule."
Advertisements
The research was conducted in the Academic Unit of Reproductive and Developmental Medicine and was funded by the Medical Research Council (MRC) and Jessop Wing Ellen Webster Legacy. The findings are published in the Journal of Biological Chemistry.
Advertisements